Axsome Therapeutics, Inc.
AXSM
NASDAQ·Healthcare·Biotechnology·Mkt cap $10.6B
$206.68
▼ -0.80%
P/E
-55.11
Mkt Cap
$10.6B
52-Wk Range
$112.90–$260.19
52-Week Range
$112.90 - $260.19
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 59.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Advanced multi-mechanistic drug development
- Diverse clinical-stage pharmaceutical pipeline
- Strategic research collaborations
- Focused neurological treatment expertise
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Moderate growth ahead
Expanding CNS treatment market
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Weak
-12.1% over 3m
Quality
Excellent
High-growth business (57% revenue growth, 93% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying AXSM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 2, 2026
AUG 10, 2026
Reported EPS of -$0.99 vs -$0.89 consensus (-11.0% surprise). Revenue of $216.4M vs $221.1M expected (-2.1%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-11.0%
Revenue trend · last 8Q
—
+66%
+62%
+72%
+63%
+65%
+57%
+46%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$104.8M
$118.8M
$121.5M
$150.0M
$171.0M
$196.0M
$191.2M
$218.4M
Margins · last 8Q
Gross
93.8%
Operating
-22.7%
Profit
-23.5%
Wall Street consensus
12 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: UBS · Aug 24, 2026
vs Industry
How AXSM stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related